Table 2.

Efficacy

Best response	Evaluable patients (n = 23)		AITL (n = 14)		PTCL-NOS (n = 6)
	Number	Response rate, n (%)	Number	Response rate, n (%)	Number	Response rate, n (%)
ORR	15	65.2	11	78.6	3	50
CR	6	26.1	5	35.7	1	16.7
PR	9	39.1	6	42.9	2	33.3
SD	2	8.7	1	7.1	1	16.7
PD	6	26.1	2	14.3	2	33.3
Median Follow-up	15.7 mo
Median time to BR	86 d
2-y PFS (n = 23) (%)	31.5 (95% CI, 16.1-61.5)
2-y OS (n = 23) (%)	49.5 (95% CI, 31.6-77.8)

BR, best response; PD, progression of disease; PR, partial response; SD, stable disease.